Cabazitaxel in the treatment of castration-resistant cancer: hitting the balance of efficacy and safety

Abstract

Cabazitaxel, an antineoplastic agent from the third generation taxan group, has demonstrated efficacy in the treatment of metastatic castration-resistant prostate cancer (mCRPC) refractory to docetaxel. This article is devoted to a critical analysis of studies on the use of cabazitaxel in this category of patients and key aspects of management of treatment-related toxicity. The authors also reviewed possible scenarios for the use of cabazitaxel in the sequential therapy of mCRPC, including androgen receptor signalling inhibitors and systemic radiotherapy.